Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps
- 13 July 2012
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 3 (5) , 227-239
Abstract
Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disorder of the brain caused by a ubiquitous polyomavirus, JC virus. PML is almost always associated with some underlying immunosuppression and acquired immune deficiency syndrome has been the most common predisposing disorder. Recently, different pharmacological agents have been demonstrated to increase the risk of PML. Therapies that predispose people to PML can be classified into three categories: therapies that uniquely increase the risk for the disorder, such as the monoclonal antibodies natalizumab and efalizumab; therapies that appear to increase the risk in individuals already at risk of PML due to pre-existing conditions, such as rituximab and mycophenolate mofetil; and therapies with a mechanism of action that might suggest a potential for increased PML risk and/or with which rare cases of PML have been observed. Unlike the latter two classes, therapeutic agents uniquely increasing the risk of PML are associated with a much greater prevalence of the disorder and a latent interval from the time of drug initiation to the development of PML. PML development with pharmacological agents has provided new insight into the pathogenesis of this devastating disorder. This review focuses on the risks of PML with multiple pharmacological agents, the proposed pathogenesis with these agents, and potential risk mitigation strategies.Keywords
This publication has 87 references indexed in Scilit:
- Fatal PML associated with efalizumab therapyNeurology, 2012
- Role for tumor necrosis factor-alpha in JC virus reactivation and progressive multifocal leukoencephalopathyJournal of Neuroimmunology, 2011
- Progressive Multifocal Leukoencephalopathy and Newer Biological AgentsDrug Safety, 2010
- Monoclonal antibody therapy in multiple sclerosismAbs, 2010
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood, 2009
- Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: Are patients with systemic lupus erythematosus at particular risk?Autoimmunity Reviews, 2008
- Blockade of CD11a by Efalizumab in Psoriasis Patients Induces a Unique State of T-Cell HyporesponsivenessJournal of Investigative Dermatology, 2008
- Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasisBritish Journal of Dermatology, 2008
- Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJournal of Neuroimmunology, 2006
- Involvement of JC Virus–Infected Mononuclear Cells from the Bone Marrow and Spleen in the Pathogenesis of Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 1988